Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL1357155

N.N.N.N.N.NNN

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210154323-A1 FUNCTIONALIZED NANOPARTICLES FOR THE INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES AND METHODS FOR THEIR MANUFACTURE AND USE STEMGENICS, INC. (US) 2021-05-27 US disclosed
EP-3463316-A2 FUNCTIONALIZED NANOPARTICLES FOR THE INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES AND METHODS FOR THEIR MANUFACTURE AND USE Stemgenics, Inc. (US) 2019-04-10 EP disclosed
US-20180223260-A1 FUNCTIONALIZED NANOPARTICLES FOR THE INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES AND METHODS FOR THEIR MANUFACTURE AND USE STEMGENICS, INC. (US) 2018-08-09 US disclosed
US-9944534-B2 Reducing aluminosilicate scale in the Bayer process ECOLAB USA INC. (US) 2018-04-17 US disclosed
WO-2017210666-A2 FUNCTIONALIZED NANOPARTICLES FOR THE INTRACELLULAR DELIVERY OF BIOLOGICALLY ACTIVE MOLECULES AND METHODS FOR THEIR MANUFACTURE AND USE STEMGENICS, INC. (US) 2017-12-07 WO disclosed
US-20170050861-A1 Reducing Aluminosilicate Scale in the Bayer Process NALCO COMPANY (US) 2017-02-23 US disclosed
US-9487408-B2 Reducing aluminosilicate scale in the bayer process NALCO COMPANY (US) 2016-11-08 US disclosed
WO-2013126683-A1 REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS NALCO COMPANY (US) 2013-08-29 WO disclosed
US-8420055-B2 Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor VISEN MEDICAL, INC. (US) 2013-04-16 US disclosed
US-20120148462-A1 REDUCING ALUMINOSILICATE SCALE IN THE BAYER PROCESS ECOLAB USA INC. 2012-06-14 US disclosed
EP-1469989-B1 AMINE FUNCTIONALIZED SUPERPARAMAGNETIC NANOPARTICLES FOR THE SYNTHESIS OF BIOCONJUGATES VISEN MEDICAL INC (US) 2011-12-14 EP disclosed
US-20110282122-A1 MOLECULAR SIEVE, CATALYST, AND/OR A PROCESS RELATING THERETO UOP, LLC (US) 2011-11-17 US disclosed
WO-2011143031-A2 MOLECULAR SIEVE, CATALYST, AND/OR A PROCESS RELATING THERETO UOP LLC (US) 2011-11-17 WO disclosed
US-20090068115-A1 Amine Functionalized Superparamagnetic Nanoparticles for the Synthesis of Bioconjugates and Uses Therefor VISEN MEDICAL, INC. 2009-03-12 US disclosed
EP-1469989-A4 AMINE FUNCTIONALIZED SUPERPARAMAGNETIC NANOPARTICLES FOR THE SYNTHESIS OF BIOCONJUGATES AND USES THEREFOR VISEN MEDICAL INC (US) 2006-07-05 EP disclosed
EP-1469989-A2 AMINE FUNCTIONALIZED SUPERPARAMAGNETIC NANOPARTICLES FOR THE SYNTHESIS OF BIOCONJUGATES AND USES THEREFOR Visen Medical, Inc. (US) 2004-10-27 EP disclosed
WO-2003057175-A2 AMINE FUNCTIONALIZED SUPERPARAMAGNETIC NANOPARTICLES FOR THE SYNTHESIS OF BIOCONJUGATES AND USES THEREFOR VISEN MEDICAL, INC. (US) 2003-07-17 WO disclosed
US-20030124194-A1 Amine functionalized superparamagnetic nanoparticles for the synthesis of bioconjugates and uses therefor VISEN MEDICAL, INC. 2003-07-03 US disclosed
US-5981507-A A CONJUGATED PRODRUGS FOR THE TREATMENT OF VIRAL INFECTIONS AND CANCER WITH SUBSTANTIALLY ENHANCED THERAPEUTIC EFFICACY AND REDUCES TOXICITY ADVANCED MAGNETICS, INC. (US) 1999-11-09 US disclosed
WO-1997021452-A2 MACROMOLECULAR PRODRUGS OF NUCLEOTIDE ANALOGS ADVANCED MAGNETICS, INC. (US) 1997-06-19 WO disclosed